Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Short-term Investments (2016 - 2022)

Catalyst Pharmaceuticals (CPRX) has disclosed Short-term Investments for 12 consecutive years, with $19.4 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Short-term Investments changed N/A year-over-year to $19.4 million, compared with a TTM value of $19.4 million through Mar 2022, changed N/A, and an annual FY2021 reading of $19.8 million, up 97.4% over the prior year.
  • Short-term Investments was $19.4 million for Q1 2022 at Catalyst Pharmaceuticals, down from $19.8 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $58.5 million in Q2 2018 and bottomed at $5.0 million in Q4 2019.
  • Average Short-term Investments over 5 years is $28.8 million, with a median of $23.3 million recorded in 2019.
  • The sharpest move saw Short-term Investments surged 120.44% in 2018, then crashed 86.44% in 2019.
  • Year by year, Short-term Investments stood at $36.9 million in 2018, then plummeted by 86.44% to $5.0 million in 2019, then soared by 100.54% to $10.0 million in 2020, then skyrocketed by 97.4% to $19.8 million in 2021, then dropped by 2.0% to $19.4 million in 2022.
  • Business Quant data shows Short-term Investments for CPRX at $19.4 million in Q1 2022, $19.8 million in Q4 2021, and $20.0 million in Q3 2021.